Literature DB >> 26912747

A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV Variants.

Pierre Cappy1, Fabienne De Oliveira2, Marie Gueudin1, Elodie Alessandri-Gradt1, Jean-Christophe Plantier3.   

Abstract

The cocirculation of different HIV types and groups can lead to dual infections and recombinants, which hinder diagnosis and therapeutic management. We designed two multiplex PCRs (mPCRs) coupled with capillary electrophoresis to facilitate the detection of such infections. The first, MMO2, targets three variants (HIV-1/M, HIV-1/O, and HIV-2), and the second, MMO, targets HIV-1/M and HIV-1/O. These mPCRs were validated on DNA and RNA extracts from 19 HIV-1/M, 12 HIV-1/O, and 13 HIV-2 cultures and from mixtures simulating dual infections. They were then assessed with DNA and RNA extracts from samples of 47 clinical monoinfections and HIV-1/M+O dual infections or infections with HIV-1/MO recombinants. Both mPCRs had excellent specificity. Sensitivities ranged from 80 to 100% for in vitro samples and from 58 to 100% for clinical samples, with the results obtained depending on the material used and the region of the genome concerned. Sensitivity was generally lower for DNA than for RNA and for amplifications of the integrase and matrix regions. In terms of global detection (at least one target gene for each strain), both mPCRs yielded a detection rate of 100% for in vitro samples. MMO2 detected 100% of the clinical strains from DNA and 97% from RNA, whereas MMO detected 100% of the strains from both materials. Thus, for in vitro and clinical samples, MMO2 was a useful tool for detecting dual infections with HIV-1 and HIV-2 (referred to as HIV-1+HIV-2) and HIV-1/M+O, and MMO was useful for detecting both MO dual infections and MO mosaic patterns.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26912747      PMCID: PMC4844735          DOI: 10.1128/JCM.03222-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  47 in total

1.  First evidence of transmission of an HIV-1 M/O intergroup recombinant virus.

Authors:  Paul Alain Ngoupo; Serge Alain Sadeuh-Mba; Fabienne De Oliveira; Valérie Ngono; Laure Ngono; Patrice Tchendjou; Véronique Penlap; Thomas Mourez; Richard Njouom; Anfumbom Kfutwah; Jean-Christophe Plantier
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

2.  An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.

Authors:  F Damond; A Benard; Claudia Balotta; Jürg Böni; Matthew Cotten; Vitor Duque; Bridget Ferns; Jeremy Garson; Perpetua Gomes; Fátima Gonçalves; Geoffrey Gottlieb; Bernd Kupfer; Jean Ruelle; Berta Rodes; Vicente Soriano; Mark Wainberg; Audrey Taieb; Sophie Matheron; Genevieve Chene; Francoise Brun-Vezinet
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

3.  Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses.

Authors:  F Simon; S Souquière; F Damond; A Kfutwah; M Makuwa; E Leroy; P Rouquet; J L Berthier; J Rigoulet; A Lecu; P T Telfer; I Pandrea; J C Plantier; F Barré-Sinoussi; P Roques; M C Müller-Trutwin; C Apetrei
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

4.  Highly sensitive plasma RNA quantification by real-time PCR in HIV-2 group A and group B infection.

Authors:  Séverine Delarue; Emmanuelle Didier; Florence Damond; Diane Ponscarme; Karen Brengle-Pesce; Matthieu Resche-Rigon; Muriel Vray; Marie Gueudin; François Simon
Journal:  J Clin Virol       Date:  2013-08-14       Impact factor: 3.168

5.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.

Authors:  Huldrych F Günthard; Milo Huber; Herbert Kuster; Cyril Shah; Jörg Schüpbach; Alexandra Trkola; Jürg Böni
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

7.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

8.  Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaboration.

Authors:  Boris K Tchounga; Andre Inwoley; Patrick A Coffie; Daouda Minta; Eugene Messou; Guillaume Bado; Albert Minga; Denise Hawerlander; Coumba Kane; Serge P Eholie; François Dabis; Didier K Ekouevi
Journal:  J Int AIDS Soc       Date:  2014-08-11       Impact factor: 5.396

Review 9.  HIV-2: the forgotten AIDS virus.

Authors:  Thushan I de Silva; Matthew Cotten; Sarah L Rowland-Jones
Journal:  Trends Microbiol       Date:  2008-10-27       Impact factor: 17.079

10.  Discovery of functional genomic motifs in viruses with ViReMa-a Virus Recombination Mapper-for analysis of next-generation sequencing data.

Authors:  Andrew Routh; John E Johnson
Journal:  Nucleic Acids Res       Date:  2013-10-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.